GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Total Long-Term Liabilities

Tryptamine Therapeutics (ASX:TYP) Total Long-Term Liabilities : A$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Tryptamine Therapeutics's Total Long-Term Liabilities for the quarter that ended in Dec. 2024 was A$0.00 Mil.

Tryptamine Therapeutics Total Long-Term Liabilities Historical Data

The historical data trend for Tryptamine Therapeutics's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Total Long-Term Liabilities Chart

Tryptamine Therapeutics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Long-Term Liabilities
Get a 7-Day Free Trial - 0.60 0.82 0.35 0.04

Tryptamine Therapeutics Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.05 0.04 0.03 -

Tryptamine Therapeutics Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Tryptamine Therapeutics Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Total Long-Term Liabilities
Comparable Companies
ASX:RAD ASX:ILA ASX:LTP ASX:CYP ASX:PIQ ASX:PTX ASX:SPL ASX:NUZ ASX:ACW ASX:EZZ VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
TYPTF:USA
Address
C/o Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Website
https://www.tryptherapeutics.com
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).

Tryptamine Therapeutics Headlines

No Headlines